At the European Congress of Radiology (ECR) 2024, Hologic, a leading force in women’s health, unveils groundbreaking AI research. Dr. Sarah M. Friedewald presents studies showcasing the prowess of Hologic’s Genius AI® Detection solution in breast cancer detection and workflow enhancement. These findings highlight AI’s transformative potential in radiology, promising improved patient care. Alongside, Hologic and Bayer co-sponsor a symposium on contrast-enhanced mammography (CEM), featuring eminent radiologists Dr. Jacopo Nori and Dr. Marc Lobbes. The symposium provides insights into the effective implementation of CEM in daily practice. With plans for a global rollout, Hologic’s Genius AI Detection technology signifies a paradigm shift in breast imaging diagnostics, empowering radiologists worldwide with cutting-edge AI solutions.
Hologic, renowned for its innovations in women’s health, showcases groundbreaking AI research at ECR 2024. Led by Dr. Sarah M. Friedewald, these studies present advancements in breast cancer detection and workflow optimization through Hologic’s Genius AI® Detection solution. This research underscores AI’s potential to revolutionize radiology practices, elevating standards of patient care. Complementing these revelations, Hologic and Bayer co-sponsor a symposium on contrast-enhanced mammography (CEM), chaired by esteemed radiologists Dr. Jacopo Nori and Dr. Marc Lobbes. The symposium aims to equip radiologists with insights into integrating CEM effectively into their daily routines. Together, these initiatives mark a significant stride towards enhancing women’s health globally.
As the pioneering force behind 3D mammography, Hologic will unveil new data demonstrating how next-generation deep-learning solutions can revolutionize breast cancer detection and streamline workflow for radiologists. Dr. Sarah M. Friedewald, an esteemed breast imaging specialist and Chief of Breast Imaging at Northwestern Memorial Hospital, will present the research findings. Dr. Friedewald’s research highlights the remarkable capability of Hologic’s Genius AI® Detection solution to accurately match pairs of Regions of Interest (ROIs) across different views, marking a significant advancement in AI-assisted diagnosis.
Dr. Friedewald remarked, “These data underscore the unprecedented potential of AI to augment radiologists’ workflow and elevate the standard of patient care. The transformative impact of AI extends beyond daily practices, promising improvements across the entire spectrum of breast health.”
Furthermore, Dr. Friedewald will present research demonstrating how the Genius AI Detection algorithm can detect potential cancers on mammograms previously interpreted as normal. Additionally, another study will showcase Hologic’s deep learning-based AI algorithm’s superiority over traditional machine learning Computer-Aided Detection (CAD) algorithms, notably in specificity and overall effectiveness.
Tanja Brycker, Vice President of Strategic Development for Breast & Skeletal Health and Gynecological Surgical Solutions at Hologic, emphasized the company’s commitment to research and education. “We’re thrilled to unveil groundbreaking research at ECR and to continue our partnership with Bayer on contrast-enhanced mammography. Through our collaboration, we aim to empower radiologists with the latest advancements and ensure confident patient care procedures and decisions.”
Hologic and Bayer will jointly host a symposium on contrast-enhanced mammography (CEM), featuring distinguished breast imaging radiologists Dr. Jacopo Nori and Dr. Marc Lobbes. The symposium, scheduled for Thursday, February 29 at 11 a.m. CET, will provide radiologists with insights into the effective integration of CEM into their daily practice.
Hologic’s Genius AI Detection technology, a state-of-the-art solution, is currently available in the U.S. and is slated for rollout in Europe, Canada, and Asia by the end of 2024. This expansion will enable healthcare providers worldwide to harness the power of AI for enhanced diagnostic accuracy and improved patient outcomes.
Hologic’s participation at ECR 2024 signifies its commitment to advancing women’s health through cutting-edge technology and collaborative education. Dr. Sarah M. Friedewald’s presentations shed light on the transformative capabilities of Hologic’s Genius AI® Detection solution in breast cancer detection and workflow enhancement. These findings reinforce the pivotal role of AI in radiology, promising improved patient outcomes worldwide. The co-sponsored symposium on contrast-enhanced mammography (CEM) further enriches the discourse, providing radiologists with actionable insights for integrating CEM into their clinical practices effectively. As Hologic’s Genius AI Detection technology prepares for a global rollout, it heralds a new era in breast imaging diagnostics, empowering healthcare professionals to deliver superior care with confidence.
